New Stock News | AHB submitted an application to the Hong Kong Stock Exchange, with market shares of L-Alanine and L-Valine ranking first globally

According to the Hong Kong Stock Exchange's disclosure on September 30, the Anhui AHB Biotechnology Co., Ltd. (abbreviated as AHB, 688639.SH) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Huatai International as the sole sponsor.

According to the prospectus, as a pioneer in global synthetic biotechnology, AHB focuses on the research and development, large-scale production, and commercialization of bio-based products relying on biomanufacturing technology. The company possesses cutting-edge R&D capabilities, strong technological innovation capabilities, and mature mass production capabilities, committed to transforming laboratory technological achievements into green, low-carbon, and high-performance bio-based products and solutions to meet emerging application scenarios. With twenty years of deep cultivation in the biomanufacturing field, the company has established an industry-leading position in R&D, technology, and market.

According to Frost & Sullivan data: the company is one of the most comprehensive bio-based product companies globally that achieve commercial application through synthetic biotechnology; it is the world's first company to industrialize a series of amino acids (including L-Alanine and L-Valine) through anaerobic fermentation; and based on 2024 revenue, the company's market share of L-Alanine and L-Valine ranks first globally.

As of June 30, 2025, the company has established stable long-term cooperative relationships with over 768 customers in 85 countries across major markets in Asia, Europe, and America. As of June 30, 2025, the company's bio-based products mainly include amino acid series products (mainly alanine series, L-Valine, Tryptophan, Arginine); vitamin series products (mainly D-Calcium Pantothenate, D-Pantothenol, Inositol); and other bio-based products (mainly bio-based new material monomers (1,3-Propanediol and Succinic Acid), Malic Acid, Arbutin), etc. The company's bio-based products are widely used in various industries, including animal nutrition, daily chemical care, food and beverage, advanced materials, and plant nutrition.

The company adopts two major green manufacturing technology platforms: fermentation and enzyme catalysis, centering around microbial cell factories for fermentation production processes and enzyme catalysis for enzyme production processes, constructing a core technology group covering strain construction, intelligent fermentation, efficient purification and separation, and product development. Relying on its technological system, the company's biomanufacturing methods replace traditional chemical synthesis processes with renewable biological resources, thereby reducing pollution, lowering energy consumption, and minimizing carbon footprints.

According to the Frost & Sullivan report, the global bio-based product market is expected to increase from USD 22.8 billion in 2020 to USD 42.1 billion in 2024, with a compound annual growth rate (CAGR) of 16.6%. It is anticipated to further increase from USD 80.1 billion in 2030 to USD 109.1 billion in 2035, with a CAGR of 11.3% from 2024 to 2030, and a CAGR of 6.4% from 2030 to 2035 Against this backdrop, companies with green manufacturing capabilities, large-scale production technology, and advantages in industrial chain collaboration will usher in unprecedented development opportunities.

In terms of performance, the company achieved revenues of approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively; during the same period, the annual/profit for the period was approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million.